January 29, 2026 – Porton Advanced proudly announces that its client, CSPC Pharmaceutical Group Limited, has received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA) for its proprietary "SYS6055 Injection", an innovative in vivo CAR‑T therapy. This milestone marks the first in vivo CAR‑T therapy approved for clinical trials in China, indicated for the treatment of relapsed or refractory aggressive B‑cell lymphoma. Porton Advanced extends its sincere congratulations to CSPC on this achievement.
CSPC was established in 1997. Since the very beginning, CSPC has taken “All for better medicine, all for a healthier world” as its corporate mission. In all aspects of development, procurement, production and distribution, we are committed to ensuring the health of people by creating high-quality, effective, reliable, and innovative drugs that meet the needs of society.
Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.
Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites, and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 24 global IND approvals from NMPA, FDA, and Medsafe, with 11 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.
Porton Advanced’s Lentivirus CDMO platform provides clients with a reliable supply chain and cost-efficiency manufacturing. The company has a proven track record of delivering multiple GMP batches of in vivo CAR-T products to global partners, achieving viral titers of 1×10⁹ TU/mL and batch production scales up to 1×10¹² TU. Its fully integrated, end-to-end CDMO platform provides comprehensive solutions from plasmid and lentiviral vector manufacturing to final CAR-T cell, supporting both ex vivo and in vivo CAR‑T therapeutic approaches. The platform also enables development and production of a wide range of cell and gene therapy products, including gene‑editing technologies, viral vectors, and cell‑based therapeutics.
Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.
Porton Advanced’s End-to-End Cell Therapy CDMO Service Accelerates NMPA Approval of Gene MiNK Biotechnology’s Innovative NK Therapy
Gene MiNK Biotechnology’s Innovative BCMA-targeted CAR-NK Therapy Secures NMPA IND Approval, Accelerated by Porton Advanced’s Comprehensive End-to-End Cell Therapy CDMO Service
Porton Advanced’s End-to-End CDMO Service Drives Qihan Biotech’s First-in-Class Dual-targeting CAR-T IND Approval in China
Porton Advanced and RongCan Biotech Announce Strategic Collaboration to Advance LNP Delivery Technology for Nucleic Acid and Cell Therapies
Porton Advanced and NovaCell Therapeutics Announced Strategic Cooperation to Accelerate NK Cell Therapy Development
Porton Advanced’s End-to-End Bacterial Vector CDMO Solution Accelerates FDA Approval of Salvectors’ Innovative Oncolytic Bacteria Therapy